Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
enGene Holdings Inc. stock logo
ENGN
enGene
$3.96
-0.8%
$3.99
$2.65
$12.80
$201.87M-0.36133,020 shs22,663 shs
Scilex Holding stock logo
SCLX
Scilex
$5.65
+7.6%
$6.12
$3.60
$80.50
$39.28M1.161,181 shs117,195 shs
Septerna, Inc. stock logo
SEPN
Septerna
$9.86
+1.4%
$7.00
$4.17
$28.99
$439.34MN/A711,475 shs431,444 shs
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
$5.91
+1.9%
$5.94
$1.16
$10.37
$315.84M0.5395,058 shs235,175 shs
Free Today: Your Guide to Smarter Options Trades Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
enGene Holdings Inc. stock logo
ENGN
enGene
-0.75%-7.69%-1.00%-34.11%-67.99%
Scilex Holding stock logo
SCLX
Scilex
+7.62%+20.73%+22.56%-31.60%-85.84%
Septerna, Inc. stock logo
SEPN
Septerna
+1.44%+4.01%+42.28%+52.40%+985,999,900.00%
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
+1.90%-5.14%-11.39%-9.08%+237.71%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
enGene Holdings Inc. stock logo
ENGN
enGene
3.1623 of 5 stars
3.55.00.00.01.82.50.6
Scilex Holding stock logo
SCLX
Scilex
2.4713 of 5 stars
3.33.00.00.02.71.70.6
Septerna, Inc. stock logo
SEPN
Septerna
2.5803 of 5 stars
3.40.00.00.04.01.70.6
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
1.8266 of 5 stars
3.51.00.00.02.70.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
enGene Holdings Inc. stock logo
ENGN
enGene
3.00
Buy$23.29488.02% Upside
Scilex Holding stock logo
SCLX
Scilex
2.60
Moderate Buy$455.007,953.10% Upside
Septerna, Inc. stock logo
SEPN
Septerna
2.75
Moderate Buy$27.00173.83% Upside
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
3.00
Buy$8.5043.82% Upside

Current Analyst Ratings Breakdown

Latest SCLX, TKNO, SEPN, and ENGN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/16/2025
Septerna, Inc. stock logo
SEPN
Septerna
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$20.00 ➝ $25.00
5/16/2025
Septerna, Inc. stock logo
SEPN
Septerna
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$11.00 ➝ $18.00
4/29/2025
enGene Holdings Inc. stock logo
ENGN
enGene
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$18.00 ➝ $18.00
4/11/2025
Scilex Holding stock logo
SCLX
Scilex
D Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
4/11/2025
Scilex Holding stock logo
SCLX
Scilex
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold
4/2/2025
Scilex Holding stock logo
SCLX
Scilex
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$770.00 ➝ $630.00
3/28/2025
Septerna, Inc. stock logo
SEPN
Septerna
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$14.00 ➝ $11.00
3/11/2025
enGene Holdings Inc. stock logo
ENGN
enGene
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$37.00 ➝ $34.00
3/11/2025
enGene Holdings Inc. stock logo
ENGN
enGene
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$25.00 ➝ $25.00
2/28/2025
Scilex Holding stock logo
SCLX
Scilex
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$770.00 ➝ $770.00
(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
enGene Holdings Inc. stock logo
ENGN
enGene
N/AN/AN/AN/A$6.17 per shareN/A
Scilex Holding stock logo
SCLX
Scilex
$50.71M0.77N/AN/A($1.10) per share-5.14
Septerna, Inc. stock logo
SEPN
Septerna
$977K449.68N/AN/AN/A
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
$38.25M8.26N/AN/A$2.21 per share2.67
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
enGene Holdings Inc. stock logo
ENGN
enGene
-$55.14M-$1.52N/AN/AN/AN/A-16.69%-14.27%6/10/2025 (Estimated)
Scilex Holding stock logo
SCLX
Scilex
-$114.33M-$29.02N/AN/AN/A-159.10%N/A-93.65%8/12/2025 (Estimated)
Septerna, Inc. stock logo
SEPN
Septerna
N/AN/A0.00N/AN/AN/AN/AN/A6/26/2025 (Estimated)
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
-$36.78M-$0.48N/AN/AN/A-87.17%-35.30%-24.52%N/A

Latest SCLX, TKNO, SEPN, and ENGN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
6/26/2025Q1 2025
Septerna, Inc. stock logo
SEPN
Septerna
-$0.38N/AN/AN/AN/AN/A
6/10/2025Q2 2025
enGene Holdings Inc. stock logo
ENGN
enGene
-$0.4768N/AN/AN/AN/AN/A
5/15/2025Q1 2025
Septerna, Inc. stock logo
SEPN
Septerna
-$0.38-$0.49-$0.11-$0.49N/A$0.22 million
5/8/2025Q1 2025
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
-$0.11-$0.09+$0.02-$0.09$9.41 million$9.60 million
3/27/2025Q4 2024
Septerna, Inc. stock logo
SEPN
Septerna
-$0.69-$0.64+$0.05-$0.64$0.13 million$0.21 million
3/4/2025Q4 2024
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
N/A-$0.11N/A-$0.11$9.10 million$9.27 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
enGene Holdings Inc. stock logo
ENGN
enGene
$1.5839.92%N/AN/A N/A
Scilex Holding stock logo
SCLX
Scilex
N/AN/AN/AN/AN/A
Septerna, Inc. stock logo
SEPN
Septerna
N/AN/AN/AN/AN/A
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
enGene Holdings Inc. stock logo
ENGN
enGene
0.08
16.87
16.87
Scilex Holding stock logo
SCLX
Scilex
N/A
0.14
0.13
Septerna, Inc. stock logo
SEPN
Septerna
N/AN/AN/A
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
0.12
4.73
3.94

Institutional Ownership

CompanyInstitutional Ownership
enGene Holdings Inc. stock logo
ENGN
enGene
64.16%
Scilex Holding stock logo
SCLX
Scilex
69.67%
Septerna, Inc. stock logo
SEPN
Septerna
N/A
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
13.81%

Insider Ownership

CompanyInsider Ownership
enGene Holdings Inc. stock logo
ENGN
enGene
10.40%
Scilex Holding stock logo
SCLX
Scilex
7.65%
Septerna, Inc. stock logo
SEPN
Septerna
4.30%
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
15.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
enGene Holdings Inc. stock logo
ENGN
enGene
3150.98 million38.16 millionN/A
Scilex Holding stock logo
SCLX
Scilex
806.95 million222.07 millionOptionable
Septerna, Inc. stock logo
SEPN
Septerna
N/A44.56 millionN/AN/A
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
24053.44 million45.21 millionNot Optionable

Recent News About These Companies

BTIG Reaffirms Their Hold Rating on Alpha Teknova (TKNO)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
enGene stock logo

enGene NASDAQ:ENGN

$3.96 -0.03 (-0.75%)
Closing price 05/29/2025 04:00 PM Eastern
Extended Trading
$4.15 +0.19 (+4.77%)
As of 05/29/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

Scilex stock logo

Scilex NASDAQ:SCLX

$5.65 +0.40 (+7.62%)
Closing price 05/29/2025 04:00 PM Eastern
Extended Trading
$5.63 -0.02 (-0.35%)
As of 05/29/2025 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California.

Septerna stock logo

Septerna NASDAQ:SEPN

$9.86 +0.14 (+1.44%)
Closing price 05/29/2025 04:00 PM Eastern
Extended Trading
$9.86 0.00 (-0.01%)
As of 05/29/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body. Due to their significant role in human diseases, GPCRs have been the most productive target class in drug discovery history, accounting for approximately one-third of all U.S. Food and Drug Administration (FDA) approved drugs, representing approximately 500 products with combined global revenue of approximately $125 billion in 2023. Despite the pharmacological and commercial success of GPCR-targeted agents, about 75% of potential GPCR therapeutic targets remain undrugged and, for certain validated GPCRs, novel binding pockets may exist that could offer enhanced therapeutic benefits. Each step in GPCR activation involves subtle conformational changes that have been historically challenging to reproduce outside of a cell. The inability to isolate GPCR proteins in their native functional form outside of a cellular context has prevented scientists from leveraging some of the state-of-the-art technologies that have revolutionized drug discovery in other major target classes over the past decade. This complex challenge has limited GPCR drug discovery, particularly the development of novel oral small molecules, such as agonists (which activate GPCR signaling) for peptide GPCRs and allosteric modulators (which either increase or decrease the degree of GPCR activation by endogenous ligands). Our proprietary Native Complex Platform™ replicates the natural structure, function, and dynamics of GPCRs outside of cells at an industrial scale for, as we believe it, the first time. Our foundational technologies enable us to isolate, purify, and reconstitute full-length, properly folded GPCR proteins within ternary complexes with ligands and transducer proteins in a lipid bilayer that mimics the cell membrane. We then apply state-of-the-art discovery tools and technologies to these defined and tunable protein complexes to structurally design, screen for, and optimize potential product candidates. Leveraging our platform, we conduct GPCR oral small molecule drug discovery using an industrialized and iterative structure-based drug design approach for a diverse collection of GPCR targets. Our Native Complex PlatformTM is designed to enable us to target specific GPCRs, uncover novel binding pockets for validated receptors, and pursue a wide spectrum of pharmacologies, including agonists, antagonists (which inhibit GPCR signaling), and allosteric modulators, to affect GPCR signaling in different ways to achieve desired therapeutic effects. We are advancing a deep portfolio of oral small molecule GPCR-targeted programs with novel mechanistic approaches to treat diseases across multiple therapeutic areas for patients with significant unmet needs. Our wholly-owned pipeline, is focused initially on three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. We intend to evaluate opportunities in other major therapeutic areas, such as neurology, women's health, cardiovascular, and respiratory disease. --- Leveraging our team, scientific and technical advisors, and our proprietary Native Complex Platform™, we aim to be a leader in the development of oral GPCR-targeted medicines for patients with significant unmet needs. We were incorporated under the laws of the State of Delaware in December 2019 under the name GPCR NewCo, Inc. and changed our name to Septerna, Inc. in June 2021. Our principal executive offices are located at 250 East Grand Avenue, South San Francisco, California.

Alpha Teknova stock logo

Alpha Teknova NASDAQ:TKNO

$5.91 +0.11 (+1.90%)
Closing price 05/29/2025 04:00 PM Eastern
Extended Trading
$5.76 -0.15 (-2.52%)
As of 05/29/2025 05:03 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alpha Teknova, Inc. produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.